MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.07
-0.11
-1.08%
After Hours: 10.07 0 0.00% 16:00 01/28 EST
OPEN
10.15
PREV CLOSE
10.18
HIGH
10.44
LOW
10.00
VOLUME
193.59K
TURNOVER
--
52 WEEK HIGH
32.84
52 WEEK LOW
9.40
MARKET CAP
380.40M
P/E (TTM)
-7.1011
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AUTL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AUTL News

  • The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
  • Benzinga.16h ago
  • Autolus Announces Closing of Public Offering of $7.25M ADS At $11 per ADS
  • Benzinga.1d ago
  • Autolus Announces Closing of Public Offering
  • GlobeNewswire.1d ago
  • Autolus Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting
  • GlobeNewswire.1d ago

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About AUTL

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.
More

Webull offers Autolus Therapeutics Ltd - ADR (AUTL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.